

Glucocorticoids for Human Skin: New Aspects of the Mechanism of Action

M. Schäfer-Korting^a B. Kleuser^a M. Ahmed^a H.-D. Höltje^b H.C. Korting^c^aPharmakologie und Toxikologie, Institut für Pharmazie, Freie Universität Berlin, Berlin,^bPharmazeutische Chemie, Institut für Pharmazie, Heinrich-Heine-Universität, Düsseldorf,^cKlinik und Poliklinik für Dermatologie und Allergologie, Ludwig-Maximilians-Universität, München, Deutschland

Key Words

Glucocorticoids · Genomic effects · Glucocorticoid receptor · Non-genomic effects · Cellular signalling · Skin

Abstract

Topical glucocorticoids have always been considered first-line drugs for inflammatory diseases of the skin and bronchial system. Applied systemically, glucocorticoids are used for severe inflammatory and immunological diseases and the inhibition of transplant rejection. Owing to the progress in molecular pharmacology, the knowledge of the mechanism of action has increased during the last years. Besides distinct genomic targets, which are due to the activation of specific cytoplasmatic receptors resulting in the (trans-) activation or (trans-) repression of target genes, there are non-genomic effects on the basis of the interference with membrane-associated receptors as well as with membrane lipids. In fact, various glucocorticoids appear to differ with respect to the relative influence on these targets. Thus, the extended knowledge of glucocorticoid-induced cellular signalling should allow the design and development of even more specifically acting drugs – as it has been obtained with other steroids, e.g. estrogens for osteoporosis prevention.

Copyright © 2005 S. Karger AG, Basel

Introduction

Cortisol, the most potent physiologic glucocorticoid, affects almost all physiologic systems of the organism. Cortisol is synthesised and released from the adrenal cortex under hypothalamic control in a pulsatile and circadian way. Importantly, under stress the adrenals secrete cortisol on top of this rhythm, which facilitates recovery. In case of immune challenge, cortisol protects the organism against damaging inflammatory responses. Due to the multiple targets of action, cortisol and more importantly synthetic derivatives are first-line drugs in the treatment of immunologic and inflammatory diseases, as for example inflammatory bowel disease, arthritis and systemic lupus erythematosus. Moreover, glucocorticoids are effective in the treatment of some neoplastic diseases, e.g. acute lymphatic leukemia of children.

In many inflammatory skin diseases [1] as well as in persistent bronchial asthma [2], topical glucocorticoids are a mainstay of therapy, as unwanted effects are less prominent compared with systemic treatment. With respect to the skin, antiproliferative, apoptotic or antiapoptotic and also vasoconstrictive effects may contribute to the desired anti-inflammatory and immunosuppressive effects, yet may also result in unwanted side effects in other diseases. Moreover, it has been learnt that glucocorticoids do not only differ with respect to potency but also in the benefit/risk ratio [3], which is linked to a selective influence on cytokine synthesis [4, 5]. While this was first

reported concerning topical glucocorticoid use in dermatology, recently this has also been acknowledged with respect to asthma therapy [6–10]. The understanding of this separation increases since several new aspects of the glucocorticoid signalling pathways were revealed during the last years, expanding our knowledge on the mechanism of drug action. Various aspects of glucocorticoid action have been reviewed previously emphasising comparison of glucocorticoids and other immunomodulators [11], non-genomic glucocorticoid effects [12–14], cross-talk with cytokines and transcription factors [15–18], glucocorticoid-mediated apoptosis [19], receptor isoforms [20] but also effects in asthma [9, 21]. Here, we describe the multifaceted aspects of the mechanism of glucocorticoid action which are currently known and their translation into the therapy of inflammatory skin diseases.

Influence on the Cytokine Network

An imbalance of helper T cells in atopic eczema and asthma results in an increased baseline mediator formation [22]. Consequently, alveolar macrophages of asthma patients and keratinocytes of patients with atopic dermatitis release interleukin-1 (IL-1), tumour necrosis factor- α (TNF- α) and granulocyte-macrophage colony-stimulating factor (GM-CSF) at an increased rate [21, 23–25]. By stimulating cytokine receptors on the cell surface, IL-1 and TNF- α induce a cellular signal cascade which activates transcription factors such as signal transducers and activators of transduction (STATs) or the nuclear factor κ B (NF- κ B) which is released from the complex with its inhibitory protein I κ B α . Another relevant pathway of IL-1 and TNF- α is the activation of the mitogen-activated protein (MAP) kinase, and thus the activation of activator protein 1 (AP-1) which also results in the activation of nuclear factor of activated T cells (NFAT) containing AP-1 as an integral part. AP-1 and NF- κ B activate response genes by binding to their promoter region, recruitment of co-activators and basal transcription factors. Histone acetylation by activated histone acetyl transferases results in a more relaxed chromatin environment which enables the access of RNA polymerase to the coding region of the target gene. These are genes coding for cytokines (IL-1, IL-2, IL-4, IL-6, IL-13, TNF- α), chemotaxis proteins (e.g., GM-CSF), cellular adhesion molecules, i.e. intercellular adhesion molecule (ICAM-1), vascular cell adhesion molecule (VCAM-1), but also enzymes, i.e. phospholipase A₂, inducible forms of cyclooxygenase (COX-2) and NO synthase (iNOS).

By inducing cellular adhesion molecules, proinflammatory cytokines (e.g., TNF α , IL-1) increase epidermal chemokine formation and T cell localisation. CCL17 and CCL22, chemokines with two highly conserved adjacent cysteine residues formed by IL-4 and IL-13 stimulation, recruit T cells to skin and lung. Keratinocytes from patients with atopic dermatitis express also other Th attractant chemokines such as RANTES, MCP-1 and – most importantly – CCL27 more abundantly [23, 24].

Most importantly, there is an intense cross-talk of the various signalling pathways described, and maximum activation of a cell means the activation of more than a single pathway. Moreover, enzymes from the MAP kinase pathway may also interact with the NF- κ B cascade [15, 16].

By inhibiting the formation of inflammatory cytokines, glucocorticoids interfere with the activation of a variety of immunologic cells. Glucocorticoids inhibit the activation of dendritic cells which normally stimulate Th2 cells and in the lung also B cells. Moreover, eosinophil and T cell apoptosis increases. Yet, glucocorticoids also influence other cells such as keratinocytes, fibroblasts and alveolar cells. Besides genomic effects, non-genomic targets appear to contribute to glucocorticoid effects.

Genomic Glucocorticoid Effects

Receptor Structure

In general, steroid hormones induce their effects by binding to intracellular receptors (glucocorticoid receptor, GR or hGR α ; mineralocorticoid receptor, MR; progesterone receptor, PR; androgen receptor, AR; estrogen receptor, ER; fig. 1) which are closely interrelated and form a superfamily together with the receptors for thyroid hormone, retinoids, vitamin D but also the peroxisome proliferator activated receptor. Today, various isoforms of these receptors are known. These proteins are characterised by an N-terminal domain activating gene expression, a central DNA-binding moiety and a C-terminal ligand-binding domain.

The highly conserved central DNA-binding domain of about 70 residues contains two loops which are stabilised by four cysteine residues each complexing to zinc ions (zinc fingers). The N-terminal zinc finger discriminates between the different response elements and therefore is important for the selectivity of glucocorticoid effects. The DNA-binding domain is flanked by an N-terminal transactivating moiety (τ 1) which after receptor binding enhances the transcription of target genes. The ligand-bind-




Fig. 1. Human glucocorticoid receptor gene, mRNA splice variants and receptor proteins (hGR α and hGR β); modified from [20].




Fig. 2. Glucocorticoid receptor binding as determined experimentally [30, 81]. BM = Betamethasone; BMP = betamethasone dipropionate; BMV = betamethasone 17-valerate; BU = budesonide; CBP = clobetasol 17-propionate; DEX = dexamethasone; MOM = mometasone; MPD = methylprednisolone; PC = prednicarbate; PD = prednisolone; TAA = triamcinolone acetonide.

ing domain is built up from 12 α -helices, the segment $\tau 2$ of the liganded receptor, which is part of helix 12, favours dimerisation and enhances transactivation but also interactions with co-activators [26]. The closest homology is found within the group of the 3-oxo-steroid receptors which besides GR are the MR, PR and AR. The ligand-binding domains contain a central arginine and a glutamine complexing the 3-keto group, while it is glutaminic

acid and arginine of ER which interact with the phenolic group of the estrogens [26, 27].

Recently, the precise structure of the ligand-binding domain of GR was revealed by the crystallisation of this domain [28] and independently by molecular modeling starting from the well-known ligand-binding domain of PR [29, 30]. The C-terminal 12 helices of the GR fold into a three-layer sandwich which embeds the hydropho-

Table 1. Glucocorticoid receptor binding predicted from quantitative structure activity calculations and experimentally determined [30, 81, 82], IC₅₀ values for genomic and non-genomic effects in A549 cells [7] and relative activity in rheumatic diseases [13]

Glucocorticoid	Binding		Genomic effects			Non-genomic effects	
	calculated	determined	growth inhibition	COX-2	PGE ₂	AA/PLA ₂	antirheumatic activity
Dexamethasone	7.87	8.02 8.03	8.30	7.00	7.70	7.70	1.2
Methylprednisolone	7.39	7.43	8.30	NS	8.00	8.00	1.0
Fluticasone	NR	9.3	<12.00	9.30	9.30	NS	ND
Mometasone	8.97	8.79 9.12	<12.00	10.00	11.00	NS	ND
Budesonide	8.48 ¹	9.00	10.30	9.00	9.00	NS	ND
Beclomethasone dipropionate	8.70 ¹	ND	12	9.12	9.12	NS	ND
Beclomethasone	7.86 ¹	ND	9.60	6.70	7.70	7.70	ND
Prednylidene	7.52 ¹	ND	ND	ND	ND	ND	3.0
Prednisolone	7.12	6.99	9.00	7.30	7.30	NS	0.4
Betamethasone	8.07	7.60	ND	ND	ND	ND	0.2
Betamethasone 17-valerate	9.38	9.15	ND	ND	ND	ND	ND
Betamethasone dipropionate	8.08	8.20	ND	ND	ND	ND	ND
Prednicarbate	7.81	7.89	ND	ND	ND	ND	ND
Clobetasol 17-propionate	9.65	9.82	ND	ND	ND	ND	ND
Hydrocortisone	7.20 ¹	ND	8.00	7.12	7.12	7.12	ND
Triamcinolone acetonide	8.44 ¹	8.31	7.60	6.70	6.70	6.70	ND

ND = Not determined; NR = reliable results not to be expected; NS = not significant.

¹ Recalculated as described by [30].

bic pocket for the ligand. In contrast to other nuclear receptors, there is a rather wide side pocket which allows access of many steroid esters favoured for the topical treatment of inflammatory skin diseases and bronchial asthma. Results of ligand docking experiments to predict glucocorticoid activity conformed to steroid binding determined experimentally. As depicted in figure 2, there is a close correlation of GR binding predicted by quantitative structure activity calculations and the binding data determined experimentally. Extending the set of 17 steroids [30] by another seven (table 1) the only exception is fluticasone propionate, calculation of binding data is excluded since this agent is the only carbothiolate drug.

Non-stimulated GRs form a complex with various receptor-associated proteins (RAPs) which mask the ligand-binding domain. RAPs are chaperones (heat shock proteins hsp90 and hsp70) which ensure correct folding of the receptor protein and co-chaperones such as the immunophilin FKB51 [18], a FK506 (tacrolimus)-binding protein.

Receptor Activation, Response Elements, Transactivation and Transrepression

Glucocorticoid binding induces hyperphosphorylation, exchange of immunophilins (FKB52 replaces FKB51) and recruitment of the transport protein dynein which allows nuclear translocation of the receptor. In the nucleus, ligand-activated GRs release hsp90 and change structure [18] which allows the formation of a unique homodimer characterised by a β -sheet made up from the dimerisation domains of both monomers [28]. GR dimers as transcription factors bind to specific DNA-binding elements (glucocorticoid response elements; GREs) and influence the expression of target genes which harbour the respective response elements in their promotor region (simple GRE, transactivation; fig. 3a). Simple GREs are imperfect palindromic 15-base-pair sequences which are recognised by the zinc fingers of the DNA-binding domains of activated receptors. Gene inducibility increases with the numbers of response elements in the vicinity of the polymerase-binding moiety. Composite GREs allow additional binding for non-receptor factors




Fig. 3. Models describing glucocorticoid interactions with DNA and transcription factors (modified from [18]; for details see text).

[18]. Glucocorticoid-induced transactivation is seen, e.g. with genes related to gluconeogenesis, arterial blood pressure and intraocular tension which harbour GREs as does the gene encoding the β_2 -adrenoceptor.

Besides inducing gene expression by binding of a homodimer to a GRE, glucocorticoids may also inhibit gene expression either by the binding of liganded monomers to a promoter containing negative GREs (nGREs; fig. 3b) or by the sequestration or inhibition of basal transcription factors (fig. 3c–e). nGREs differ in structure from classic GREs and were first described for the proopiomelanocortin gene [21] and then for others, e.g. the IL-1 β gene [18]. In epidermal cells, the synthesis of basal-cell-specific (K5, K14) and disease-associated keratins (K6, K16, K17) is under the control of four nGREs [31]. Another form of inhibited gene expression has been known even longer. This is due to the complex formation of liganded GR monomers and the basal transcription factors described

above which then become inactivated either by sequestration (fig. 3c), masking of transactivation domains (fig. 3d) or steric hindrance of the basal transcription machinery (fig. 3e). Residues of the GR DNA and ligand-binding domains interact with AP-1, the DNA-binding domain is involved in the complex formation with NF- κ B.

Helix 12 of the activated GR allows co-activator and/or co-repressor interaction [28], including the steroid receptor co-activator (SRC)-1 and the cAMP-responsive element-binding protein (CREB)-binding protein (CBP). Increasing histone acetylation co-activators (fig. 3f) weaken histone-chromatin interactions which enables polymerase to initiate transcription, while the opposite holds true with histone deacetylase. By binding to co-factors, glucocorticoids reverse these effects on gene expression. In addition, glucocorticoids may influence gene expression by histone methylation and phosphorylation (for review, see [9]).

Table 2. Glucocorticoid activation and suppression of genes relevant for the efficacy in inflammatory skin diseases and skin atrophy induction (from [18])

Inhibition of	Gene	Transcription factor
Cytokines	IL-2	NF-AT, AP-1, NF-κB
	IL-6	NF-κB, AP-1
	TNF-α GM-CSF, IL-1β	NF-κB
	IFN-γ	AP-1
Enzymes	iNOS, COX-2	NF-κB
	collagenase	AP-1
Adhesion molecules	ICAM-1, E-selectin, VCAM-1	NF-κB
Skin proliferation	keratin	GR monomer (nGRE)
	collagenase	AP-1

Another genomic effect includes the increase in glucocorticoid-inducible leucine zipper and thus AP-1 [18] and NF-κB formation in macrophages [32]. Inhibition of lymphocyte and monocyte activation by the NF-κB pathway (fig. 3g) is due to an enhanced transcription of the IκBα gene [21, 33, 34] which, however, is not the case with murine fibroblasts, endothelial cell lines [35] and human keratinocytes [5]. Table 2 summarises signalling pathways which are influenced by glucocorticoids.

Moreover, glucocorticoids interfere with the formation of inflammatory proteins also at the post-transcriptional level by mRNA destabilisation as described for, e.g., TNF-α, IL-1, IL-2, IL-6, COX-2 and iNOS [18].

Glucocorticoid Antagonists

As with other nuclear receptors, GR antagonists have been developed. Most frequently used for in vitro and animal experiments is RU486 (mifepristone) which inhibits dexamethasone-induced transactivation, while it acts as a partial agonist with respect to AP-1 and NF-κB suppression [36–38]. RU486 also induces immunophilin exchange, dynein recruitment and nuclear translocation [39]. In man, RU486 suppresses the symptoms and signs of hypercortisolism and dexamethasone-induced pituitary inhibition and skin blanching [40]. Most interestingly, the glucocorticoid antagonist ZK98299 acts in a more specific manner as the liganded GR does not interfere with NF-κB activity [36, 37]. This distinct interaction offers the horizon to more selective GR ligands.

Receptor Isoforms

Several isoforms of the human GR can be differentiated. Only in rare cases, however, point mutations or splice variants may result in diseases, e.g. rare forms of the glucocorticoid resistance syndrome [20]. The most important form is the broadly distributed α-form (hGRα; fig. 1) containing 777 amino acids which is expressed in

high amounts in almost all cell types including keratinocytes and fibroblasts [41], endothelial cells of blood vessels and the airway epithelium as well as the epithelium of bronchial vessels [21].

Breslin et al. [42] identified two more exons upstream of exon 1, which can translate into exon 1 of the hGR protein; these are therefore named exons 1A and 1B, while exon 1, known for a longer period now, is called exon 1C. Moreover, alternative translation initiation of exon 1 (1C) results in the formation of a B isoform of hGRα which consists of 751 residues [43]. Currently, the tissue distribution and possible differences in function of the isoforms differing in the transactivating domain await to be discovered.

Another broadly distributed isoform, named hGRβ, is generated from a splice variant of exon 9 of the GR gene and is found in human tissues (e.g., lung, thymus, lymphocytes, brain, heart, muscle), though it is present at a lower rate as compared with hGRα (1:40–2,800) [20]. Both isoforms are identical until amino acid 727, then 15 different residues follow in hGRβ. Due to the truncated C-terminal domain, hGRβ does not bind ligands any more and is transcriptionally inactive itself. Early investigations suggested a negative effect of hGRβ on hGRα effects [44, 45]. This, however, may be related to some tissues or cell states only [20]. A protective effect of hGRβ against dexamethasone induced apoptosis of human neutrophils [46] and a correlation of hGRβ expression, and glucocorticoid resistance were described [47–49]. Yet, the relevance of hGRβ for asthma is still under debate [9, 49, 50]. Following cotransfection of hGRα and hGRβ genes, transactivation declined by 40% in COS-7 cells and to a lesser extent in the lung carcinoma cell line A549. Most interestingly, overexpression of either isoform inhibited transrepression – even in the absence of dexamethasone stimulation which might be due to complex formation of even the non-liganded GR and transcription factors [50].

hGR α mRNA also clearly dominates in primary cultures of human keratinocytes (328-fold) and fibroblasts (710-fold) over hGR β mRNA. Increasing hGR β over hGR α fivefold by cotransfection of COS-7 cells did not reduce the binding of glucocorticoids and RU486 significantly [41]. In skin biopsies, hGR β is upregulated during tuberculin response [48]. All these ratios, however, have to be interpreted with caution since mRNA ratios must not translate 1:1 to the protein level and the quantification of the protein is related to antibody specificity.

Another truncated splice variant (GR- δ ; exon 8) detected in tumour cells or the rather ubiquitously expressed hGR- γ do not seem to be of major clinical relevance [20]. Yet, this may be different with two other recently described polymorphisms. An S651F mutation of hGR α was identified in immortalised lymphocytes isolated from atopic Japanese, resulting in the formation of a less stable and therefore less active GR protein. Stability of mRNA was even more reduced if adenine was inserted into position 2314 of hGR α gene. Detected with lymphocytes taken from patients suffering from lupus nephritis, this polymorphism may reduce the efficacy of glucocorticoid therapy [51].

Concerning tissue specificity, another GR polymorphism deserves to be mentioned, which is due to alternative splicing of human GR gene by two forms of the DNA restriction enzyme BclI. While this does not change the coding region of the GR gene, it may influence the regulating region [18]. Most interestingly, the large variant of the restriction enzyme was linked to increased sensitivity to budesonide-induced skin blanching, while dexamethasone more efficiently inhibited lysozyme release from leukocytes from subjects with the small allele [52]. Once more, this hints at tissue-specific effects of various glucocorticoids.

In the context of GR isoforms, also the GR^{dim} mouse has to be mentioned, which is transfected with a GR isoform unable for dimer formation and thus transactivation, yet inducing transrepression as the wild type does. Therefore, in contrast to the GR knockout mice, the GR^{dim} mouse grows until adulthood [53].

Modulation of Responsiveness

Besides GR isoforms and the numbers and locations of GREs in the promotor, post-translational processes regulate glucocorticoid responsiveness. Hyperphosphorylation of serins in the $\tau 1$ region of the liganded GR enhances the response to steroids by favouring ligand binding, RAP binding and nuclear trafficking, while GR dephosphorylation reduces transactivation. Moreover,

glucocorticoid response is influenced by the cross-talk of nuclear receptor signalling pathways, since the liganded GR does not only form a homodimer, but also heterodimers with the other nuclear receptors and can compete with those for co-factors [18]. Also receptor-associated immunophilins may induce a cross-talk with other signalling cascades as to be derived from studies in synovial fibroblasts [54] and the lung adenocarcinoma-derived A549 cell [8] stimulated with dexamethasone and FK506.

Recently, tyrosine nitration has been described as a mechanism to enhance GR hsp90 dissociation and anti-inflammatory activity. Nitration, including the important Tyr735 [29], was induced by a GR ligand carrying a nitration domain [55]. This observation may stimulate the search for new and possibly more specific drugs.

Glucocorticoid Resistance

Whether hGR β is of relevance with respect to glucocorticoid resistance which occurs, e.g. in up to 10% of asthmatic subjects but also in other chronic inflammatory diseases, currently remains open. Alternatively, a reduced number of activated GR within the nucleus, a lack of interaction with the basal transcription process, or a hyperactive MAP kinase pathway may be the reason for this steroid resistance [15]. It can only be speculated whether one of these mechanisms may be of relevance also in glucocorticoid tachyphylaxia, which was a subject of major concern in the early days of topical glucocorticoid treatment of skin disease [56].

Non-Genomic Glucocorticoid Effects

While it takes at least 30 min for the genomic effects to become obvious in a cell culture experiment, it takes only seconds or a few minutes to detect non-genomic effects. As with other steroids, non-genomic targets were identified also with glucocorticoids [12–14]. Membrane-associated receptors appear to be a specific isoform or a modification of the classical GR. Steroid effects on membrane-associated receptors encompass the activation of MAP kinase, adenylate cyclase and protein kinase C [18]. Glucocorticoids inhibit the recruitment of signalling factors of activated epithelial growth factor receptors and thus phospholipase A₂ and arachidonic acid release [57]. Investigations of various glucocorticoids in A549 cells allowed to separate three types of glucocorticoids (table 1; fig. 3). The conventional steroids dexamethasone, hydrocortisone, triamcinolone acetonide and beclomethasone induced both genomic (COX-2 expression, prostaglandin

E release and inhibition of cell growth) and non-genomic effects (phospholipase A₂ activation and arachidonic acid release). The latter was proven by its sensitivity to the SRC-1 inhibitor PP2 and insensitivity to the translocation inhibitor geldanamycin. In contrast, methylprednisolone exhibited only the non-genomic effect, while the newly developed steroids fluticasone 17-propionate, mometasone and budesonide but also beclomethasone dipropionate did not induce phospholipase A₂ activity, yet selectively inhibited COX-2 expression, prostaglandin E release, and cell growth [7]. In fact, these steroids are reported to induce less side effects in asthma therapy as compared with conventional steroids. These data clearly indicate that a separation of glucocorticoid effects is possible. Since RU486 inhibited genomic and non-genomic effects, the latter should be induced by the stimulation of membrane-associated GR.

If applied at very high concentrations (prednisolone >200 mg), which are used for, e.g., shock therapy, glucocorticoids can also induce non-specific non-genomic effects, possibly due to a physical dissolution of the steroid molecule within the cell membrane. This results in a partial uncoupling of oxidative phosphorylation, mitochondrial proton leak and a decrease of cellular entry of calcium ions which may explain that high glucocorticoid doses are generally needed for acute exacerbations of immunological diseases. Relative glucocorticoid potencies for non-specific non-genomic effects [58] clearly differ from potency for genomic effects (table 1). With respect to the topical treatment of skin disease or bronchial asthma, local drug concentrations high enough to induce non-specific non-genomic drug actions currently cannot be excluded.

Glucocorticoid Effects on the Skin

Despite of the recent introduction of calcineurin inhibitors into the topical treatment of eczema, glucocorticoids still are first-line drugs, especially with respect to the acute treatment of the more severe forms [1]. Yet, topical glucocorticoids are also indicated for other inflammatory skin diseases, as for example psoriasis. This is due to the inhibition of the formation of inflammatory proteins released from keratinocytes, fibroblasts and leukocytes infiltrating the skin. Unwanted effects most feared are skin thinning which is due to the inhibition of keratin synthesis of epidermal cells [31] and, more importantly, to an impaired proliferation of fibroblasts [5, 59, 60] and disturbed collagen metabolism in the dermis. In the rat,

dexamethasone induced a drastical reduction of the fibril type III collagen and – less – type I collagen. Moreover, this drug decreased collagenases which belong to the matrix metalloproteinases (MMP) and tissue inhibitors of the metalloproteinases TIMP-1 and TIMP-2 [61]. In fact, collagenase (MMP-13) produced by basal keratinocytes is under AP-1 control and the formation is downregulated by dexamethasone treatment of both wild-type and the GR^{dim} mice [33]. Since type I and type III collagens primarily determine the tensile strength of the skin [62], this deterioration explains well striae formation which occurs in hypercortisolism and may follow long-term topical treatment with glucocorticoids [63]. Moreover, the effect on K5 and K14 explains epidermal thinning during long-term glucocorticoid treatment, inhibition of K6 and K16 the interference with wound healing. The additional effect on keratin synthesis via AP-1 inhibition may increase glucocorticoid effects, since besides nGREs these keratin gene promoters also contain an AP-1 response site [31].

Glucocorticoids induce cytostatic and cytotoxic effects in a cell-specific manner [62]. While apoptosis induction is a well-known effect of glucocorticoids interfering with NF-κB in lymphocytes, and the inhibition of immune cells should contribute to its immunosuppressive and anti-inflammatory effects in eczema and psoriasis, skin thinning following glucocorticoids is not due to an increased apoptotic rate. In fact, despite an inhibition of NF-κB activity, dexamethasone protected fibroblasts against the TNFα, UV irradiation or ceramide-induced apoptosis by stimulating sphingosine 1-phosphate (S1P) formation. While NF-κB inhibitors did not abolish the antiapoptotic effect, the sphingosine kinase inhibitor N,N-dimethylsphingosine did so. This effect is cell specific as it was not seen with keratinocytes [64]. Although we previously demonstrated that vitamin D₃ and the transforming growth factor-β stimulate fibroblast proliferation via an increased sphingosine phosphorylation [65, 66] and S1P then activates Smad proteins [67], the S1P-induced proliferation is obviously overrun by the antiproliferative effect of glucocorticoids due to the inhibition of IL-1α and IL-6 release [5].

Glucocorticoids: Benefit/Risk Ratio in Eczema Therapy

Since target diseases for glucocorticoid treatment are of chronic or relapsing nature, drugs efficacious and safe in the long-run are of highest relevance. The unraveling

of signalling processes offers new perspectives for safer therapeutic strategies. Antiproliferative effects of topical glucocorticoids, however, do not parallel steroid potency in man [68, 69] or cell culture [5]. When looking into the molecular reason for the partial separation of wanted and unwanted effects obtained so far, one has to take the multi-faceted mechanism of action into account.

Comparing hGR α binding of 17 topical glucocorticoids widely varying in potency (prednisolone to clobetasole 17-propionate) did not allow to detect an influence of receptor affinity on the benefit/risk ratio. In fact, binding of less atrophogenic steroids fitted well into the spectrum of the more toxic agents [30]. Moreover, calculated receptor binding of six glucocorticoids studied for their influence on A549 cells are well in accordance with previous data (table 1, fig. 2). Yet as with asthma, the differences in the benefit/risk ratio in eczema may result from differences in transrepression, transactivation and specific non-genomic effects [7] undistinguished by receptor binding. Interestingly, low glucocorticoid concentrations appear to induce transrepression more potently than transactivation [9]. The influence on NF- κ B transrepression, however, did not reflect the potential in skin diseases. Indeed, clobetasol propionate activity only slightly exceeded the hydrocortisone effect [38]. Differentiating steroids with a favourable effect on transrepression in vitro [70, 71], however, failed in the animal experiment [72]. Therefore, additional targets appear of relevance.

Mometasone and the relatively equipotent fluticasone propionate [73] both belong to the group of glucocorticoids with an improved benefit/risk ratio [69]. At lower concentrations, they bind preferentially to GR monomers, and induce dimer formation only at higher concentrations [6]. In addition, a separation of budesonide and dexamethasone effects has been described in subjects expressing different GR isoforms [52].

Therefore, the specific interaction of a glucocorticoid with the GR may influence the structure of the receptor surface and thus its interaction with other proteins and GREs. In fact, recently differing requirements of GR targets for τ 1 and τ 2 structures were reported [62], and full and partial GR agonists differing in D ring structure induce different receptor conformational changes [29]. Interestingly, prednicarbate, which proved less atrophogenic than betamethasone 17-valerate and also less than mometasone [69], turned out as a partial agonist with the N564A mutant of hGR α [30].

Since glucocorticoid effects depend on the cell type, cell culture experiments, especially if performed in cell lines or using protein overexpression, may not exactly

reflect glucocorticoid effects in vivo. In fact, glucocorticoids less atrophogenic to the skin (mometasone furoate, fluticasone propionate) strongly inhibit the proliferation of A549 cells (table 1) [7]. Detecting skin-specific effects asks for studies in vivo or at least in primary skin cell cultures. Doing so, however, does not eliminate the 'time' factor, since cell culture experiments are run for some hours, while the treatment of skin diseases lasts for days or even weeks which allows for adaptative processes. Therefore, it is to be expected that in vivo experiments will improve further our understanding of glucocorticoid-related differences in wanted and unwanted effects.

Future Developments

Glucocorticoid research is an ongoing process for more than 50 years, and its intensity is currently increasing. New congeners of a somewhat improved benefit/risk ratio have been developed [63], more selective ones are to be expected. Current research aims at designing drugs inducing selective transrepression [71, 72] or enhancing binding by nitrotyrosine formation [55]. Increasing target selectivity at the molecular level, however, may bear the risk of a major loss in efficacy.

An alternative for a safer eczema therapy therefore encompasses drug carrier systems for epidermal glucocorticoid targeting [74, 75]. Moreover, combined treatment with tretinoin should reduce skin atrophy [76, 77], and ointment preparations containing a glucocorticoid plus a vitamin D analogue may improve psoriasis therapy by reducing side effects [78]. Studies in rheumatoid synovial [54] and murine skin fibroblasts [79] also indicate a synergistic effect of tacrolimus and low-dose dexamethasone which may translate into clinical improvement. Due to the still measurable potential for skin atrophy of glucocorticoids and the lower potency and the risk of photocarcinogenesis with tacrolimus and pimecrolimus [80], a combination therapy that is safe and effective in long-term treatment of severe cases would be welcome.

Acknowledgement

The authors gratefully acknowledge financial support from the Deutsche Forschungsgemeinschaft (FG 463) and the Alexander-von-Humboldt-Stiftung (personal grant to M.A.).

References

- Charman C, Williams H: The use of corticosteroids and corticosteroid phobia in atopic dermatitis. *Clin Dermatol* 2003;21:193–200.
- Leone FT, Fish JE, Szeffer SJ, West SL: Systematic review of the evidence regarding potential complications of inhaled corticosteroid use in asthma: Collaboration of American College of Chest Physicians, American Academy of Allergy, Asthma, and Immunology, and American College of Allergy, Asthma, and Immunology. *Chest* 2003;124:2329–2340.
- Schäfer-Korting M, Korting HC, Kerscher MJ, Lenhard S: Prednicarbate activity and benefit/risk ratio in relation to other topical glucocorticoids. *Clin Pharmacol Ther* 1993;54:448–456.
- Lange K, Gysler A, Bader M, Kleuser B, Korting HC, Schäfer-Korting M: Prednicarbate versus conventional topical glucocorticoids: Pharmacodynamic characterization in vitro. *Pharm Res* 1997;14:1744–1749.
- Lange K, Kleuser B, Gysler A, Bader M, Maia C, Scheiderei C, Korting HC, Schäfer-Korting M: Cutaneous inflammation and proliferation in vitro: Differential effects and mode of action of topical glucocorticoids. *Skin Pharmacol Appl Skin Physiol* 2000;13:93–103.
- Barnes P: Optimizing the anti-inflammatory effects of corticoids. *Eur Respir Rev* 2001;11:7815–7822.
- Croxtall JD, van Hal PT, Choudhury Q, Gilroy DW, Flower RJ: Different glucocorticoids vary in their genomic and non-genomic mechanism of action in A549 cells. *Br J Pharmacol* 2002;135:511–519.
- Croxtall JD, Paul-Clark M, Van Hal PT: Differential modulation of glucocorticoid action by FK506 in A549 cells. *Biochem J* 2003;376:285–290.
- Barnes PJ, Adcock IM: How do corticosteroids work in asthma? *Ann Intern Med* 2003;139:359–370.
- Kurucz I, Toth S, Nemeth K, Torok K, Csillik-Perczel V, Pataki A, Salamon C, Nagy Z, Szekely JI, Horvath K, Bodor N: Potency and specificity of the pharmacological action of a new, antiasthmatic, topically administered soft steroid, etiprednol dicloacetate (BNP-166). *J Pharmacol Exp Ther* 2003;307:83–92.
- Pfeilschifter J, Mühl H: Immunopharmacology: Anti-inflammatory therapy targeting transcription factors. *Eur J Pharmacol* 1999;375:237–245.
- Buttgereit F, Wehling M, Burmester GR: A new hypothesis of modular glucocorticoid actions: Steroid treatment of rheumatic diseases revisited. *Arthritis Rheum* 1998;41:761–767.
- Buttgereit F: Mechanisms and clinical relevance of nongenomic glucocorticoid actions. *Z Rheumatol* 2000;59(suppl 2):II/119–123.
- Falkenstein E, Tillmann HC, Christ M, Feuring M, Wehling M: Multiple actions of steroid hormones – a focus on rapid, nongenomic effects. *Pharmacol Rev* 2000;52:513–556.
- Adcock IM, Caramori G: Cross-talk between pro-inflammatory transcription factors and glucocorticoids. *Immunol Cell Biol* 2001;79:376–384.
- Refojo D, Liberman AC, Holsboer F, Arzt E: Transcription factor-mediated molecular mechanisms involved in the functional cross-talk between cytokines and glucocorticoids. *Immunol Cell Biol* 2001;79:385–394.
- Almawi WY, Melemedjian OK: Negative regulation of nuclear factor-kappaB activation and function by glucocorticoids. *J Mol Endocrinol* 2002;28:69–78.
- De Bosscher K, Vanden Berghe W, Haegeman G: The interplay between the glucocorticoid receptor and nuclear factor-kappaB or activator protein-1: Molecular mechanisms for gene repression. *Endocr Rev* 2003;24:488–522.
- Greenstein S, Ghias K, Krett NL, Rosen ST: Mechanisms of glucocorticoid-mediated apoptosis in hematological malignancies. *Clin Cancer Res* 2002;8:1681–1694.
- DeRijk RH, Schaaf M, de Kloet ER: Glucocorticoid receptor variants: Clinical implications. *J Steroid Biochem Mol Biol* 2002;81:103–122.
- Adcock IM: Glucocorticoid-regulated transcription factors. *Pulm Pharmacol Ther* 2001;14:211–219.
- Stirling RG, Chung KF: Future treatments of allergic diseases and asthma. *Br Med Bull* 2000;56:1037–1053.
- Schön MP, Zollner TM, Boehncke WH: The molecular basis of lymphocyte recruitment to the skin: Clues for pathogenesis and selective therapies of inflammatory disorders. *J Invest Dermatol* 2003;121:951–962.
- Pastore S, Mascia F, Mariotti F, Dattilo C, Girolomoni G: Chemokine networks in inflammatory skin diseases. *Eur J Dermatol* 2004;14:203–208.
- Junghans V, Gutgesell C, Jung T, Neumann C: Epidermal cytokines IL-1 β , TNF- α , and IL-12 in patients with atopic dermatitis: Response to application of house dust mite antigens. *J Invest Dermatol* 1998;111:1184–1188.
- Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engstrom O, Ohman L, Greene GL, Gustafsson JA, Carlquist M: Molecular basis of agonism and antagonism in the oestrogen receptor. *Nature* 1997;389:753–758.
- Pike AC, Brzozowski AM, Hubbard RE, Bonn T, Thorsell AG, Engstrom O, Ljunggren J, Gustafsson JA, Carlquist M: Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist. *Embo J* 1999;18:4608–4618.
- Bledsoe RK, Montana VG, Stanley TB, Delves CJ, Apolito CJ, McKee DD, Consler TG, Parks DJ, Stewart EL, Willson TM, Lambert MH, Moore JT, Pearce KH, Xu HE: Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition. *Cell* 2002;110:93–105.
- Ray DW, Suen CS, Brass A, Soden J, White A: Structure/function of the human glucocorticoid receptor: Tyrosine 735 is important for transactivation. *Mol Endocrinol* 1999;13:1855–1863.
- Hammer S, Spika I, Sippl W, Jessen G, Kleuser B, Höltje H-D, Schäfer-Korting M: Glucocorticoid receptor interactions with glucocorticoids: Evaluation by molecular modeling and functional analysis of glucocorticoid receptor mutants. *Steroids* 2003;68:329–339.
- Radoja N, Komine M, Jho SH, Blumenberg M, Tomic-Canic M: Novel mechanism of steroid action in skin through glucocorticoid receptor monomers. *Mol Cell Biol* 2000;20:4328–4339.
- Berrebi D, Bruscoli S, Cohen N, Foussat A, Migliorati G, Bouchet-Delbos L, Maillot MC, Portier A, Couderc J, Galanaud P, Peuchmaur M, Riccardi C, Emilie D: Synthesis of glucocorticoid-induced leucine zipper (GILZ) by macrophages: An anti-inflammatory and immunosuppressive mechanism shared by glucocorticoids and IL-10. *Blood* 2003;101:729–738.
- Tuckermann JP, Reichardt HM, Arribas R, Richter KH, Schutz G, Angel P: The DNA binding-independent function of the glucocorticoid receptor mediates repression of AP-1-dependent genes in skin. *J Cell Biol* 1999;147:1365–1370.
- Reichardt HM, Tuckermann JP, Göttlicher M, Vujic M, Weih F, Angel P, Herrlich P, Schutz G: Repression of inflammatory responses in the absence of DNA binding by the glucocorticoid receptor. *EMBO J* 2001;20:7168–7173.
- De Bosscher K, Schmitz ML, Vanden Berghe W, Plaisance S, Fiers W, Haegeman G: Glucocorticoid-mediated repression of nuclear factor- κ B-dependent transcription involves direct interference with transactivation. *Proc Natl Acad Sci USA* 1997;94:13504–13509.
- Heck S, Kullmann M, Gast A, Ponta H, Rahmsdorf HJ, Herrlich P, Cato AC: A distinct modulating domain in glucocorticoid receptor monomers in the repression of activity of the transcription factor AP-1. *Embo J* 1994;13:4087–4095.
- Liden J, Delaunay F, Rafter I, Gustafsson J, Okret S: A new function for the C-terminal zinc finger of the glucocorticoid receptor. Repression of RelA transactivation. *J Biol Chem* 1997;272:21467–21472.
- Hofmann TG, Hehner SP, Bacher S, Droge W, Schmitz ML: Various glucocorticoids differ in their ability to induce gene expression, apoptosis and to repress NF- κ B-dependent transcription. *FEBS Lett* 1998;441:441–446.
- Davies TH, Ning YM, Sanchez ER: A new first step in activation of steroid receptors: Hormone-induced switching of FKBP51 and FKBP52 immunophilins. *J Biol Chem* 2002;277:4597–4600.

- 40 Bertagna X: Antiglucocorticoid action of RU 486 (in French). *Ann Endocrinol (Paris)* 1989; 50:208–217.
- 41 Spika I, Hammer S, Kleuser B, Korting HC, Schäfer-Korting M: Transcriptional activity of potent glucocorticoids: Relevance of glucocorticoid receptor isoforms and drug metabolites. *Skin Pharmacol Appl Skin Physiol* 2003;16: 143–150.
- 42 Breslin MB, Geng CD, Vedeckis WV: Multiple promoters exist in the human GR gene, one of which is activated by glucocorticoids. *Mol Endocrinol* 2001;15:1381–1395.
- 43 Yudit MR, Cidlowski JA: Molecular identification and characterization of α and β forms of the glucocorticoid receptor. *Mol Endocrinol* 2001;15:1093–1103.
- 44 Bamberger CM, Bamberger AM, de Castro M, Chrousos GP: Glucocorticoid receptor β , a potential endogenous inhibitor of glucocorticoid action in humans. *J Clin Invest* 1995;95:2435–2441.
- 45 Oakley RH, Sar M, Cidlowski JA: The human glucocorticoid receptor beta isoform. Expression, biochemical properties, and putative function. *J Biol Chem* 1996;271:9550–9559.
- 46 Strickland I, Kisich K, Hauk PJ, Vottero A, Chrousos GP, Klemm DJ, Leung DY: High constitutive glucocorticoid receptor beta in human neutrophils enables them to reduce their spontaneous rate of cell death in response to corticosteroids. *J Exp Med* 2001;193:585–593.
- 47 Webster JC, Oakley RH, Jewell CM, Cidlowski JA: Proinflammatory cytokines regulate human glucocorticoid receptor gene expression and lead to the accumulation of the dominant negative beta isoform: A mechanism for the generation of glucocorticoid resistance. *Proc Natl Acad Sci USA* 2001;98:6865–6870.
- 48 Sousa AR, Lane SJ, Cidlowski JA, Staynov DZ, Lee TH: Glucocorticoid resistance in asthma is associated with elevated in vivo expression of the glucocorticoid receptor β -isoform. *J Allergy Clin Immunol* 2000;105:943–950.
- 49 Gagliardo R, Vignola AM, Mathieu M: Is there a role for glucocorticoid receptor β in asthma? *Respir Res* 2001;2:1–4.
- 50 Gougat C, Jaffuel D, Gagliardo R, Henriquet C, Bousquet J, Demoly P, Mathieu M: Overexpression of the human glucocorticoid receptor α and β isoforms inhibits AP-1 and NF- κ B activities hormone independently. *J Mol Med* 2002;80:309–318.
- 51 Koyano S, Saito Y, Nagano M, Maekawa K, Kikuchi Y, Murayama N, Fujino T, Ozawa S, Nakajima T, Matsumoto K, Saito H, Sawada J: Functional analysis of three genetic polymorphisms in the glucocorticoid receptor gene. *J Pharmacol Exp Ther* 2003;307:110–116.
- 52 Panarelli M, Holloway CD, Fraser R, Connell JM, Ingram MC, Anderson NH, Kenyon CJ: Glucocorticoid receptor polymorphism, skin vasoconstriction, and other metabolic intermediate phenotypes in normal human subjects. *J Clin Endocrinol Metab* 1998;83:1846–1852.
- 53 Reichardt HM, Kaestner KH, Wessely O, Gass P, Schmid W, Schutz G: Analysis of glucocorticoid signalling by gene targeting. *J Steroid Biochem Mol Biol* 1998;65:111–115.
- 54 Migita K, Tanaka H, Okamoto K, Yoshikawa N, Ichinose Y, Urayama S, Yamasaki S, Ida H, Kawabe Y, Kawakami A, Eguchi K: FK506 augments glucocorticoid-mediated cyclooxygenase-2 down-regulation in human rheumatoid synovial fibroblasts. *Lab Invest* 2000;80: 135–141.
- 55 Paul-Clark MJ, Roviezzo F, Flower RJ, Cirino G, Soldato PD, Adcock IM, Perretti M: Glucocorticoid receptor nitration leads to enhanced anti-inflammatory effects of novel steroid ligands. *J Immunol* 2003;171:3245–3252.
- 56 Landes E, Wolf A: 3-phase therapy. A contribution to the treatment of neurodermatitis atopica (endogenous eczema) (in German). *Z Hautkr* 1984;59:157–159.
- 57 Croxtall JD, Choudhury Q, Flower RJ: Glucocorticoids act within minutes to inhibit recruitment of signalling factors to activated EGF receptors through a receptor-dependent, transcription-independent mechanism. *Br J Pharmacol* 2000;130:289–298.
- 58 Buttgerit F: Corticoid research: In non-genomic effects there are still some questions (in German). *MMW Fortschr Med* 1999;141:81.
- 59 Korting HC, Hülsebus E, Kersch M, Greber R, Schäfer-Korting M: Discrimination of the toxic potential of chemically differing topical glucocorticoids using a neutral red release assay with human keratinocytes and fibroblasts. *Br J Dermatol* 1995;133:54–59.
- 60 Hein R, Korting HC, Mehning T: Differential effect of medium potent nonhalogenated double-ester-type and conventional glucocorticoids on proliferation and chemotaxis of fibroblasts in vitro. *Skin Pharmacol* 1994;7: 300–306.
- 61 Oishi Y, Fu ZW, Ohnuki Y, Kato H, Noguchi T: Molecular basis of the alteration in skin collagen metabolism in response to in vivo dexamethasone treatment: Effects on the synthesis of collagen type I and III, collagenase, and tissue inhibitors of metalloproteinases. *Br J Dermatol* 2002;147:859–868.
- 62 Rogatsky I, Wang JC, Derynck MK, Nonaka DF, Khodabakhsh DB, Haqq CM, Darimont BD, Garabedian MJ, Yamamoto KR: Target-specific utilization of transcriptional regulatory surfaces by the glucocorticoid receptor. *Proc Natl Acad Sci USA* 2003;100:13845–13850.
- 63 Schackert HK, Korting HC, Schäfer-Korting M: Qualitative and quantitative assessment of the benefit-risk ratio of medium potency topical corticosteroids in vitro and in vivo. *Bio-Drugs* 2000;13:267–277.
- 64 Hammer S, Sauer B, Spika I, Kleuser B, Schäfer-Korting M: Glucocorticoids mediate differential antiapoptotic effects in human fibroblasts and keratinocytes via sphingosine-1-phosphate formation. *J Cell Biochem* 2004;91: 840–851.
- 65 Manggau M, Kim DS, Ruwisch L, Vogler R, Korting HC, Schäfer-Korting M, Kleuser B: $1\alpha,25$ -dihydroxyvitamin D_3 protects human keratinocytes from apoptosis by the formation of sphingosine-1-phosphate. *J Invest Dermatol* 2001;117:1241–1249.
- 66 Vogler R, Sauer B, Kim DS, Schäfer-Korting M, Kleuser B: Sphingosine-1-phosphate and its potentially paradoxical effects on critical parameters of cutaneous wound healing. *J Invest Dermatol* 2003;120:693–700.
- 67 Sauer B, Vogler R, Von Wenckstern H, Fujii M, Anzano M, Glick AB, Schäfer-Korting M, Roberts AB, Kleuser B: Involvement of Smad-signaling in sphingosine 1-phosphate mediated biological responses of keratinocytes. *J Biol Chem* 2004;279:38471–38479.
- 68 Kersch M, Korting HC: Topical glucocorticoids of the non-fluorinated double-ester type. Lack of atrophogenicity in normal skin as assessed by high-frequency ultrasound. *Acta Derm Venereol* 1992;72:214–216.
- 69 Korting HC, Unholzer A, Schäfer-Korting M, Tausch I, Gasmueller J, Nietsch KH: Different skin thinning potential of equipotent medium-strength glucocorticoids. *Skin Pharmacol Appl Skin Physiol* 2002;15:85–91.
- 70 Vayssiere BM, Dupont S, Choquet A, Petit F, Garcia T, Marchandeu C, Gronemeyer H, Resche-Rigon M: Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit antiinflammatory activity in vivo. *Mol Endocrinol* 1997;11:1245–1255.
- 71 Vanden Berghe W, Francesconi E, De Bosscher K, Resche-Rigon M, Haegeman G: Dissociated glucocorticoids with anti-inflammatory potential repress interleukin-6 gene expression by a nuclear factor- κ B-dependent mechanism. *Mol Pharmacol* 1999;56:797–806.
- 72 Belvisi MG, Wicks SL, Battram CH, Bottoms SE, Redford JE, Woodman P, Brown TJ, Webber SE, Foster ML: Therapeutic benefit of a dissociated glucocorticoid and the relevance of in vitro separation of transrepression from transactivation activity. *J Immunol* 2001;166: 1975–1982.
- 73 Roumestan C, Henriquet C, Bousquet J, Mathieu M: Fluticasone propionate and mometasone furoate have equivalent transcriptional potencies. *Clin Exp Allergy* 2003;33:895–901.
- 74 Santos Maia C, Mehnert W, Schaller M, Korting HC, Gysler A, Haberland A, Schäfer-Korting M: Drug targeting by solid lipid nanoparticles for dermal use. *J Drug Target* 2002;10: 489–495.
- 75 Sivaramakrishnan R, Nakamura C, Mehnert W, Korting HC, Kramer KD, Schäfer-Korting M: Glucocorticoid entrapment into lipid carriers – characterisation by parrlectric spectroscopy and influence on dermal uptake. *J Control Release* 2004;97:493–502.

- 76 Lesnik RH, Mezick JA, Capetola R, Kligman LH: Topical all-trans-retinoic acid prevents corticosteroid-induced skin atrophy without abrogating the anti-inflammatory effect. *J Am Acad Dermatol* 1989;21:186–190.
- 77 Schwartz E, Mezick JA, Gendimenico GJ, Kligman LH: In vivo prevention of corticosteroid-induced skin atrophy by tretinoin in the hairless mouse is accompanied by modulation of collagen, glycosaminoglycans, and fibronectin. *J Invest Dermatol* 1994;102:241–246.
- 78 Guenther L, Van de Kerkhof PC, Snellman E, Kragballe K, Chu AC, Tegner E, Garcia-Diez A, Springborg J: Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: A randomized, double-blind, vehicle-controlled clinical trial. *Br J Dermatol* 2002;147:316–323.
- 79 Marsaud V, Mercier-Bodard C, Fortin D, Le Bihan S, Renoir JM: Dexamethasone and triamcinolone acetonide accumulation in mouse fibroblasts is differently modulated by the immunosuppressants cyclosporin A, FK506, rapamycin and their analogues, as well as by other P-glycoprotein ligands. *J Steroid Biochem Mol Biol* 1998;66:11–25.
- 80 Reitamo S, Remitz A, Kyllonen H, Saarikko J: Topical noncorticosteroid immunomodulation in the treatment of atopic dermatitis. *Am J Clin Dermatol* 2002;3:381–388.
- 81 Högger P, Rohdewald P: Binding kinetics of fluticasone propionate to the human glucocorticoid receptor. *Steroids* 1994;59:597–602.
- 82 Johnson M: Development of fluticasone propionate and comparison with other inhaled corticosteroids. *J Allergy Clin Immunol* 1998;101:S434–S439.